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ABSTRACT
Although many advantageous roles of cisplatin (cis-diamminedichloroplatinum 
(II), CDDP) have been reported in cancer therapy, the immunomodulatory roles of 
cisplatin in the phenotypic and functional alterations of dendritic cells (DCs) are 
poorly understood. Here, we investigated the effect of cisplatin on the functionality 
of DCs and the changes in signaling pathways activated upon toll-like receptor (TLR) 
stimulation. Cisplatin-treated DCs down-regulated the expression of cell surface 
molecules (CD80, CD86, MHC class I and II) and up-regulated endocytic capacity in 
a dose-dependent manner. Upon stimulation with various TLR agonists, cisplatin-
treated DCs showed markedly increased IL-10 production through activation of the 
p38 MAPK and NF-κB signaling pathways without altering the levels of TNF-α and IL-
12p70, indicating the cisplatin-mediated induction of tolerogenic DCs. This effect was 
dependent on the production of IL-10 from DCs, as neither DCs isolated from IL-10-
/- mice nor IL-10-neutralized DCs generated tolerogenic DCs. Interestingly, DCs that 
were co-treated with cisplatin and lipopolysaccharide (LPS) exhibited a decreased 
immunostimulatory capacity for inducing the proliferation of Th1- and Th17-type T 
cells; instead, these DCs contributed to Th2-type T cell immunity. Furthermore, in 
vitro and in vivo investigations revealed a unique T cell population, IL-10-producing 
CD3+CD4+LAG-3+CD49b+CD25-Foxp3- Tr1 cells, that was significantly increased 
without altering the Foxp3+ regulatory T cell population. Taken together, our results 
suggest that cisplatin induces immune-suppressive tolerogenic DCs in TLR agonist-
induced inflammatory conditions via abundant IL-10 production, thereby skewing Th 
cell differentiation towards Th2 and Tr1 cells. This relationship may provide cancer 
cells with an opportunity to evade the immune system.
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INTRODUCTION
Cisplatin (cis-DDP, cis-diamminedichloroplatinum 
(II)), a platinum-based anti-tumor drug, is one of the most 
commonly used metal-containing compounds in medicine 
[1-3]. Cisplatin and its analogues (i.e., carboplatin and 
oxaliplatin) are among the most potent chemotherapy 
drugs used for cancer treatment [1, 3]. The discovery of 
cisplatin as an anti-cancer drug in the 1960s by Rosenberg 
and colleagues ushered in a new paradigm in cancer 
treatment [3, 4]. Cisplatin is thought to damage rapidly 
growing tumor cells via the induction of apoptosis 
following the inhibition of DNA synthesis and repair, 
resulting in cell cycle arrest at the G1, S, or G2-M phase 
[1, 5, 6]. Cisplatin has clinical benefits for several types of 
solid tumors. However, cisplatin treatment is frequently 
accompanied by toxic side effects and tumor resistance, 
which in turn leads to secondary malignancies [1-3]. 
In recent years, medical research has focused on 
elucidating the mechanisms underlying cancer drugs. The 
development of new techniques to identify perturbations 
in cellular functions has increased knowledge of the 
molecular, physiological and pathological mechanisms 
of cancer drugs. In particular, emerging evidence has 
revealed the complex interplay that exists between the host 
immune system and many anti-cancer drugs. However, 
little information is available regarding how cisplatin 
interacts with immune cells. Thus, a better understanding 
of the molecular mechanisms through which cisplatin 
induces and suppresses immunological responses is 
needed to develop and optimize new therapeutic strategies 
using cisplatin. In particular, cisplatin has been shown to 
induce immunosuppressive effects through the inhibition 
of T cell activity [7, 8]. However, little is known about 
how cisplatin suppresses innate and adaptive immunity. 
Immunological interventions for tumor therapy 
have focused on two aspects: 1) immune cell-based 
tumor therapy such as dendritic cell (DC)-based tumor 
immunotherapy, and 2) immune checkpoint inhibition 
such as blocking PD-1/PD-L1. Although these two 
approaches differ, both enhance tumor-targeted Th1-type 
T cell immunity by harnessing immunological power or 
by overcoming tolerance and suppression [9-12]. In this 
regard, DCs are the most potent cell type involved in 
both strategies. In fact, DCs are the most important cell 
population for activating anti-tumor T cell responses. 
However, tumors can also directly or indirectly induce DCs 
to both functionally and phenotypically favor the tumor 
environment [12-14]. DC activation leads to a cascade of 
pro- or anti-inflammatory cytokine production, migration 
to secondary lymphoid tissues, and priming of naïve T 
cells. Therefore, these cells regulate immune homeostasis 
and the balance between tolerance and immunity [12, 13]. 
Most importantly, DCs play a critical role in regulating 
CD4 and CD8 T cell immunity by controlling Th1, Th2, 
and Th17 commitment; generating inducible Tregs; and 
mediating tolerance or immunostimulation [12, 13, 15]. It 
is believed that distinct DC subsets have evolved to control 
these different immune outcomes. However, how these 
DC subsets mount different responses to inflammatory 
and/or tolerogenic signals to accomplish their divergent 
functions remains unclear.
The effects of anti-cancer drugs on the immune 
system remain controversial. However, select 
chemotherapeutic agents primarily suppress DCs, and the 
effect of chemotherapeutic drugs on DC function requires 
further investigation in various inflammatory settings. In 
this context, we characterized the effect of cisplatin on 
the function of DCs, which play crucial roles in bridging 
innate and adaptive immunity. This study describes for the 
first time the key mechanisms involved in the switch to 
a tolerogenic DC phenotype that is induced by cisplatin 
following toll-like receptor (TLR) agonist activation of 
inflammation and the resulting consequences on T cell 
polarization. 
RESULTS
Determination of a cisplatin concentration that 
does not reduce DC viability
Cisplatin at concentrations ≥ 25 μM or ≥10 μg/ml 
induces cell death of cancer cell lines and primary cultured 
cells, such as macrophages, via DNA fragmentation [16, 
17]. Prior to conducting the current study, the viability 
of bone marrow-derived dendritic cells (BMDCs) 
exposed to cisplatin was investigated to determine a 
cisplatin concentration that does not cause cell death and 
could therefore be used in subsequent experiments. As 
expected, a cisplatin concentration over 10 μg/ml showed 
a cytotoxic effect on BMDCs when measured by MTT 
assay (Supplementary Figure S1A). Therefore, cisplatin 
concentrations ≤ 10 μg/ml were used for subsequent 
experiments, as these concentrations did not reduce 
cell viability. In addition, no significant decrease in DC 
viability following co-treatment with 10 μg/ml of cisplatin 
and 100 ng/ml of lipopolysaccharide (LPS) was observed 
by MTT assay (Supplementary Figure S1B) or Annexin V 
and propidium iodide (PI) staining (Supplementary Figure 
S1C). This finding suggests that cisplatin is not cytotoxic 
to DCs when used at concentrations below 10 μg/ml. 
Therefore, concentrations of 1 and/or 5 μg/ml of cisplatin 
were used for further investigation.
Cisplatin impairs the phenotypic maturation of 
LPS-activated DCs
Elevated expression of the co-stimulatory molecules 
CD80 and CD86 as well as MHC class I and II following 
TLR agonist stimulation is a key feature of mature DCs 
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[18]. However, the immunological actions of cisplatin, 
especially on DC maturation and function, remain 
unknown. We therefore investigated whether treatment 
with cisplatin resulted in phenotypic alteration in DCs 
upon stimulation with LPS. To accomplish this, CD11c+ 
DCs were identified using the gating strategy shown in 
Figure 1A. The DCs were cultured for 8 days in OptiMEM 
supplemented with GM-CSF under standard conditions 
and then treated with LPS (100 ng/ml), cisplatin (5 μg/
mL), or LPS (100 ng/mL) and cisplatin (1, 2, and 5 μg/
mL) for one day. The cisplatin treatment significantly 
decreased the LPS-induced expression of the co-
stimulatory molecules CD80 and CD86 and MHC class 
I and II in a dose-dependent manner, suggesting that 
cisplatin can alter the DC maturation phenotype. However, 
the DCs that were treated with cisplatin alone did not show 
any increases or decreases in these markers (Figure 1B). 
Importantly, the DCs that were co-treated with cisplatin 
(5 μg/mL) and LPS (100 ng/mL) showed significant 
reductions in the levels of the above surface molecules 
in a time-dependent manner (Supplementary Figure S2A).
Cisplatin functionally induces TLR agonist-
activated DCs toward a tolerogenic phenotype
The above findings suggest that cisplatin is involved 
in phenotypic alteration during TLR agonist-induced DC 
maturation. Thus, we hypothesized that cisplatin influences 
DC function by regulating cytokine production. To 
validate this hypothesis, we analyzed cytokine production 
in cisplatin-treated DCs following stimulation with various 
TLR ligands, including Pam3-CSK (TLR2), polyI:C 
(TLR3), LPS (TLR4), IMQ (TLR7), and ODN (TLR9). 
Surprisingly, for all of the tested TLR agonists, cisplatin 
dramatically increased the levels of the anti-inflammatory 
cytokine IL-10 in activated DCs. Furthermore, none of the 
tested TLR agonists inhibited or increased the production 
of other pro-inflammatory cytokines, such as TNF-α and 
IL-12 (Figure 2A and Supplementary Figure S3). These 
results indicate that cisplatin conditions DCs to produce 
a high amount of IL-10, independent of the specific TLR 
pathway being activated. Next, we confirmed that cisplatin 
strongly induced intracellular IL-10 production in LPS-
activated DCs. We found that DCs co-treated with cisplatin 
and LPS exhibited a significantly higher percentage of 
IL-10-positive cells and that this percentage increased 
in a dose-dependent manner, whereas no changes were 
Figure 1: Cisplatin impaired the phenotypic maturation of LPS-activated DCs by down-regulating the expression of 
CD80, CD86, MHC-I and II in a dose-dependent manner. A.,B. CD11c+ immature BMDCs were cultured for 18 h in the presence 
of LPS (100 ng/ml), cisplatin (CP, 5 μg/mL), or LPS (100 ng/mL) with cisplatin (1, 2, and 5 μg/mL). The DCs were then stained with anti-
CD80, anti-CD86, anti-MHC class I, or anti-MHC class II Abs. A. The surface marker expression of each DC set was compared to that of 
the controls. Isotype control (filled gray histogram), CON (non-stimulated DC, filled red histogram). B. The bar graphs show the mean ± SD 
(n = 3 samples) of the percentage of each surface molecule expressed by CD11c+ cells. The results are representative of three independent 
experiments. **p < 0.01 or ***p < 0.001 compared to DCs treated with LPS alone. 
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observed in the numbers of TNF-α-positive or IL-12p70-
positive cells (Figure 2B). Additionally, the co-treated 
DCs showed increased production of IL-10 in a time-
dependent manner, whereas no changes were observed 
in the production of TNF-α or IL-12p70 (Supplementary 
Figure S2B).
Figure 2: Cisplatin increased IL-10 production and endocytosis in LPS-activated DCs. A. BMDCs were treated with LPS 
(100 ng/mL) in the absence or presence of cisplatin at various concentrations (1, 2 and 5 μg/mL) for 18 h. The amounts of TNF-α, IL-12p70, 
and IL-10 in the culture supernatants were measured by ELISA. The data are shown as the mean ± SD (n = 3 samples). One representative 
plot out of three independent experiments is shown. *p < 0.05 and ***p < 0.001 compared to treatment with LPS alone. B. Intracellular 
TNF-α, IL-12p70 and IL-10 levels in CD11c+ DCs. One representative plot from three independent experiments is shown. C. The cells 
were incubated with FITC-dextran either at 37°C for 30 min or at 4°C as a control. Endocytic capacity was determined by assessing the 
endocytosis of FITC-dextran by flow cytometry (left panel). The bar graphs (right panel) indicate the mean ± SD (n = 3 samples) of the 
percentage of dextran-FITC-positive CD11c+ cells. The results are representative of three independent experiments. The values shown 
represent the mean ± SD (n = 3 samples). **p < 0.01 or ***p < 0.001 compared to DCs treated with LPS alone. 
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Cisplatin increases the endocytic activity of LPS-
activated DCs
A decrease in endocytosis is a hallmark of mature 
DCs, whereas tolerogenic DCs maintain higher endocytic 
ability [19]. To evaluate whether the antigen uptake 
ability of LPS-activated DCs is increased or decreased 
by cisplatin treatment, DCs were activated by LPS in 
the absence or presence of cisplatin and then assessed 
for their ability to uptake antigens by endocytosis using 
FITC-conjugated dextran. A significantly lower percentage 
of FITC-positive DCs were observed among the LPS-
stimulated DCs, while the cisplatin and LPS co-treatment 
enhanced the endocytic activity of DCs in a dose-
dependent manner (Figure 2C). These results, together 
with the reduction of mature DC surface markers and the 
remarkable enhancement in IL-10 production, strongly 
suggest that cisplatin endows DCs with a tolerogenic 
property upon TLR stimulation.
Cisplatin induces IL-10 secretion through 
activation of the p38 MAPK and NF-κB signaling 
pathways
Activation of the MAPK, cyclooxegenase-2 (COX-
2)/ prostaglandin E2 (PGE2) and NF-κB signaling 
cascades increases IL-10 secretion in DCs [20, 21]. To 
examine whether these pathways are involved in increased 
IL-10 production following treatment with cisplatin, 
the expression and phosphorylation levels of MAPKs, 
including p38, ERK, and JNK; the phosphorylation and 
degradation of IκB-α; and the nuclear translocation of NF-
κB p65 were investigated by Western blot analysis (Figure 
3). In DCs co-treated with cisplatin and LPS, rapid and 
Figure 3: Cisplatin-induced IL-10 production in LPS-activated DCs involved the activation of the p38 MAPK and NF-
κB signaling pathways. A. BMDCs were treated with LPS (100 ng/ml) in the absence or presence of cisplatin (5 μg/ml) for 0, 15, 30, 
60, 120, and 240 min. Cell lysates were subjected to SDS-PAGE, and immunoblot analyses were performed using Abs specific to phospho-
ERK1/2, phospho-JNK1/2 and phospho-p38. B., C. Cell lysates and nuclear lysates were subjected to SDS-PAGE, and immunoblot analyses 
were performed using Abs specific to phospho-IκB-α (p-IκB-α), non-phospho-IκB-α, and p65 NF-κB for 60 min. β-actin and lamin B were 
used as loading controls for the cytosolic and nuclear fractions, respectively. One representative plot out of three independent experiments 
is shown. D. BMDCs were treated with pharmacological inhibitors of p38 (SB203580), JNK (SP600125), or NF-κB (Bay11-7082) or 
DMSO (vehicle control) for 1 h prior to treatment with LPS in the absence or presence of cisplatin for 18 h. IL-10 levels in the culture 
medium were measured by ELISA. The values shown represent the mean ± SD from one representative plot out of three independent 
experiments; *p < 0.05, **p < 0.01, or ***p < 0.001 compared to DCs treated with LPS and cisplatin.
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prolonged p38 phosphorylation and slightly activated JNK 
phosphorylation was observed compared to DCs treated 
with LPS alone. Furthermore, ERK1/2 phosphorylation 
was decreased in the co-treated DCs compared to the 
DCs treated with LPS alone (Figure 3A). Importantly, 
treatment with cisplatin alone had no effect on MAPK 
expression and phosphorylation (Supplementary Figure 
S4A). Additionally, COX-2 activation and PGE-2 
expression were not changed by cisplatin treatment 
(Supplementary Figure S4B). Cisplatin induced the 
phosphorylation and degradation of IkB-α and the nuclear 
translocation of p65 from the cytosol (Figure 3B and 3C). 
To confirm the involvement of p38, JNK, and NF-κB in 
the above phenotypes, we next treated cells with specific 
pharmacological inhibitors (SB203580 for p38, SP600125 
for JNK, and Bay11-7082 for NF-κB) and cisplatin and 
then evaluated IL-10 production following the cisplatin 
treatment. These pharmacological inhibitors, particularly 
the p38 inhibitor, significantly abrogated cisplatin-induced 
IL-10 production in LPS-activated DCs (Figure 3D), 
suggesting that the p38 and NF-kB signaling cascades are 
the main pathways responsible for the cisplatin-induced 
production of IL-10 in LPS-activated DCs.
Cisplatin treatment conditions DCs to become 
tolerogenic through the IL-10 cascade
IL-10 induces the maturation and phenotypic 
alteration of DCs towards a tolerogenic state [22, 23]. 
Figure 4: The IL-10 cascade induced cisplatin/LPS-primed DCs to adopt a tolerogenic phenotype. A., B., C. BMDCs were 
generated from WT and IL-10-/- mice. The DCs were treated with LPS (100 ng/ml), cisplatin (5 μg/mL), or LPS with cisplatin. A. After 18 h, 
the expression of CD80, CD86, and MHC class I and II on the DCs was assessed. B. TNF-α, IL-12p70 and IL-10 levels in the supernatants 
of DCs from WT and IL-10-/- mice treated with LPS, cisplatin or LPS with cisplatin were measured by ELISA.C. Endocytic activity of 
DCs from WT and IL-10-/- mice treated with LPS, cisplatin or LPS and cisplatin was assessed at 37°C by evaluating the uptake of FITC-
conjugated dextran. The results show are representative of three independent experiments and expressed as the mean ± SD (n = 3 samples). 
*p < 0.05, **p < 0.01 and ***p < 0.001 whencomparing the WT DCs and IL-10-/- DCs before and after treatment with LPS and cisplatin.
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Figure 5: IL-10 neutralization restored the phenotypic and functional maturation of LPS-activated DCs from cisplatin-
induced tolerogenic DCs. A., B., C. BMDCs were treated with a neutralizing anti-IL-10 mAb or rat IgG (isotype control) in the absence 
or presence of LPS (100 ng/ml) or cisplatin (5 μg/ml). A. After 18 h, TNF-α, IL-12 p70 and IL-10 levels in the culture supernatants were 
measured by ELISA. B. The cells were harvested, and the surface molecule expression patterns of CD11c+ cells were measured by flow 
cytometry. C. Endocytic capacity was determined by assessing the endocytosis of FITC-dextran after IL-10 neutralization. The percentages 
of dextran-FITC positive CD11c+ cells are indicated. All bar graphs show the mean ± SD (n = 3 samples) of one representative plot from 
three independent experiments. *p < 0.05 and ***p < 0.001 between the anti-IL-10 and IgG isotype control in DCs treated with LPS and 
cisplatin.
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Thus, we hypothesized that if cisplatin-induced increases 
in IL-10 production cause LPS-activated DCs to adopt 
a tolerogenic phenotype, the absence of IL-10 should 
restore an activated DC phenotype even in the presence 
of cisplatin. To investigate whether the IL-10 increase 
stimulated by cisplatin induces DC phenotypic and 
functional changes, DCs isolated from IL-10-/- mice were 
treated with cisplatin, LPS or a combination of cisplatin 
and LPS (Figure 4). The IL-10-/- DCs displayed the LPS-
activated DC phenotype, including elevated levels of 
Figure 6: Cisplatin reduced the capacity of LPS-activated DCs to stimulate T cell proliferation and the Th1 response, 
polarized the Th2-type T cell response, and facilitated the generation of IL-10-producing Tr1 T cells. Transgenic OVA-
specific CD4+ T cells (OT-II) and transgenic OVA-specific CD8+ T cells (OT-I) were isolated; stained with CFSE; co-cultured for 96 h with 
DCs treated with LPS (100 ng/ml), cisplatin (5 μg/mL), or LPS and cisplatin; and then pulsed with OVA323-339 (1 μg/ml) for OVA-specific 
CD4+ T cells or OVA257-264 (1 μg/ml) for OVA-specific CD8+ T cells. A. The proliferation of CD4+ (left panel) and CD8+ T cells (right 
panel) was then assessed by flow cytometry. The T cell proliferation data are shown as one representative plot out of three independent 
experiments.B. Cytokine levels in the culture supernatants from CD4+ T cells (OT-II) and CD8+ T cells (OT-I) in the T cell proliferation 
experiments were measured by ELISA. C. The bar graphs show intracellular cytokine production (IFN-γ, IL-4, or IL-17A) in CD4+ 
andCD8+ T cells. D. The bar graphs show T cell transcription factor expression (T-bet for Th1, GATA-3 for Th2 and RoRγt for Th17) in 
CFSE-labeled CD4+ cells. E. The bar graphs show the percentages of Tregs and IL-10-producing Tr1 cells among CD4+ T cells. The values 
shown represent the mean ± SD (n = 4 samples) from one representative plot out of three independent experiments. *p < 0.05, **p < 0.01, 
and ***p < 0.001 compared with T cell/OVA323-339+LPS-pulsed DCs or T cells/OVA257-264 +LPS-pulsed DCs in the presence and absence of 
cisplatin.
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surface molecules (Figure 4A) and reduced endocytic 
activity (Figure 4C). However, increased levels of pro-
inflammatory cytokines (TNF-α and IL-12p70) and 
decreased levels of the anti-inflammatory cytokine IL-10 
were observed in the IL-10-/- DCs compared to WT DCs 
following co-treatment with LPS and cisplatin (Figure 
4B). We further confirmed that IL-10 induces LPS-
activated DCs to become tolerogenic following cisplatin 
treatment through experiments in which we blocked the 
IL-10 cascade with an anti-IL-10 monoclonal antibody 
(mAb) (Figure 5). Incubation of the co-treated DCs with 
an anti-IL-10 mAb, but not with control rat IgG, for 18 h 
restored their surface molecule expression levels (Figure 
5A) and IL-12p70 production (Figure 5B) and decreased 
their endocytic activity (Figure 5C). Collectively, these 
results indicate that the cisplatin-induced tolerogenic DC 
phenotype requires IL-10. 
Cisplatin-treated DCs reduce the proliferation of 
T cells and alter the polarization of T cells
Cisplatin treatment in LPS-activated DCs induced 
them to adopt a tolerogenic phenotype. Thus, we 
hypothesized that cisplatin treatment in LPS-activated 
DCs may reduce Th1 cell proliferation and alter T cell 
polarization. To precisely characterize the role of cisplatin 
in DC and T cell interactions, we performed a T cell 
proliferation assay for antigen-specific CD4+ and CD8+ T 
cells using OT-I T cell receptor (TCR) transgenic CD8+ T 
cells and OT-II TCR transgenic CD4+ T cells (Figure 6). 
LPS-treated or untreated DCs in the presence or absence 
of cisplatin were incubated with OVA257-264 or OVA323-339 
peptides, and CFSE-labeled CD4+ and CD8+ T cells were 
co-cultured. As shown in Figure 6A, the cisplatin and LPS 
co-treated DCs reduced the proliferation of both naïve 
CD4+ and CD8+ T cells compared to the LPS-treated DCs. 
Furthermore, naïve CD4+ and CD8+ T cells primed with 
Figure 7: Absence of IL-10 in DCs restored the capacity of cisplatin/LPS-primed DCs to stimulate Th1-type T cell 
proliferation. OVA-specific CD4+ and CD8+ T cells were isolated; stained with CFSE; co-cultured for 96 h with WT and IL-10-/- DCs 
treated with LPS (100 ng/ml), cisplatin (5 μg/mL), or LPS and cisplatin; and then pulsed with OVA323-339 (1 μg/ml) for OVA-specific CD4
+ 
T cells or OVA257-264 (1 μg/ml) for OVA-specific CD8+ T cells. A. The proliferation of CD4+ and CD8+ T cells was then assessed by flow 
cytometry. B. The bar graphs represent the T cell types, such as T-bet+CD4+, GATA-3+CD4+ and RoRγt+CD4+ cells, that were present among 
the CFSE-labeled CD4+ T cells. C. The bar graphs show the percentages of Treg cells and IL-10-producing Tr1 cells among the CD4+ T 
cells. All bar graphs show the mean ± SD (n = 4 samples) from one representative plot out of two independent experiments. **p < 0.01 and 
***p < 0.001 when comparing WT DCs and IL-10-/- DCs after co-treatment with LPS and cisplatin. Treatments with no significant effect 
are indicated as n.s.
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cisplatin and LPS co-treated DCs produced significantly 
lower levels of IFN-γ, IL-17A and IL-2 than those primed 
with LPS-activated DCs in a cisplatin dose-dependent 
manner (Figure 6B). These results were confirmed by 
intracellular staining (Figure 6C). Interestingly, IL-4, 
which is mainly produced by Th2-polarized T cells, was 
highly produced in CD4+ T cells primed with cisplatin and 
LPS co-treated DCs compared to those co-cultured with 
LPS-treated DCs in a cisplatin dose-dependent manner 
(Figure 6B and 6C).
We then investigated the differentiation and 
polarization of CD4+ T cells into Th1 cells, Th2 cells, 
Figure 8: Cisplatin/LPS-primed DCs impaired T cell proliferation in vivo. A., B., C. One day prior to injection with DCs 
(LPS/cisplatin-primed DC or LPS-primed DC), Ly5.2+ B6/J mice were injected with Ly5.1+ OT-I and OT-II T cells. At 5 and 7 days after 
DC injection, the frequencies of OVA-specific donor CD4+ and CD8+ T cells in PBMCs A., B. and spleen cells C. were determined by flow 
cytometry. A. The gating strategy used to detect Ly5.1+CD44+CD4+ T cell and Ly5.1+CD44+CD8+ T cell populations present in the PBMCs 
at 5 days after injection with DCs. Doublets were excluded based on forward scatter area (FSC-A) vs. forward scatter height (FSC-H), and 
dead cells were excluded by gating out cells that stained positive with LIVE/DEAD viability dye. Lymphocytes were then gated based on 
their characteristic pattern of FSC, and SSC was excluded. Activated T cells (determined by the increase of CD44 expression) gated to 
show Ly5.1+CD44+CD4+ T cell and Ly5.1+CD44+CD8+ T cell populations within the collected PBMCs and spleen cells. B. Ly5.1+CD44+ T 
cell frequency was analyzed in the PBMCs at 5 and 7 days after injection with DCs. C. Ly5.1+CD44+ T cell frequency was analyzed in the 
spleen cells at 7 days after injection with DCs. The data are expressed as the means ± SD of 4 mice in each group. *p < 0.05, **p < 0.01, 
and ***p < 0.001 compared with the group injected with LPS-primed DCs. LPS: group injected with the LPS-primed DCs (○); LPS+CP: 
group injected with the LPS/cisplatin-primed DCs (●).
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Th17 cells, regulatory T cells (Treg) and T regulatory type 
1 cells (Tr1) after priming with LPS-activated DCs in the 
presence or absence of cisplatin by analyzing transcription 
factor expression levels. Cisplatin and LPS co-treated DCs 
induced Th2 type cells (CD3+CD4+GATA-3+) and IL-
10-producing Tr1 cells (CD3+CD4+CD25-CD49b+LAG-
3+Foxp3-IL-10+) but decreased the numbers of Th1 
(CD3+CD4+T-bet+), Th17 (CD3+CD4+RoRγt+) and Treg 
Figure 9: Cisplatin/LPS-primed DCs induced the generation of Th2-type cells and IL-10-producing Tr1 cells in vivo. 
A., B., C. Spleen cells from each mouse group (i.e., mice injected with LPS-primed DCs and mice injected with Cisplatin/LPS-primed 
DCs) were stimulated with OVA257-264 and OVA323-339 for 12 h. The cells that had become stimulated with the OVA peptides were identified 
by intracellular cytokine staining of Ly5.1-expressing T cells. Further details regarding this in vivo experiment are provided in the Materials 
and Methods section. A. The frequencies of OVA-specific donor Th1 (Ly5.1+CD4+IFN-γ+), Th2 (Ly5.1+CD4+IL-4+), Th17 (Ly5.1+CD4+IL-
17A+) and IFN-γ-producing CD8+ T cells (Ly5.1+CD8+IFN-γ+) were analyzed by flow cytometry. B. The frequencies of OVA-specific donor 
IL-10-producing Tr1 cells (Ly5.1+CD4+Foxp3-CD25-IL-10+) and Treg cells (Ly5.1+CD4+Foxp3+CD25+) were analyzed by flow cytometry. 
C. Culture supernatants obtained under the conditions described in the Materials and Methods section (in vivo experiment section) were 
harvested after 12 h, and IFN-γ, IL-4, IL-17A and IL-10 levels were analyzed by ELISA. The data are shown as the means ± SD of 4 mice 
per group. *p < 0.05 and***p < 0.001 compared with the group injected with LPS-primed DCs. LPS: group injected with LPS-primed DCs 
(○); LPS+CP: group injected with LPS/cisplatin-primed DCs (●).
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cells (CD3+CD4+CD25+CD127-Foxp3+) (Figure 6D and 
6E). Additionally, cisplatin treatment produced the same 
proliferation and differentiation pattern for allogeneic T 
cells (Supplementary Figure S6). These results suggest 
that cisplatin induces the differentiation of Th2 and IL-
10-producing Tr1 cells and decreases the proliferation of 
CD4+ and CD8+ T cells in response to LPS-activated DCs.
DCs from IL-10-/- mice do not induce the 
differentiation of Th2 and Tr1 cells
IL-10-producing tolerogenic DCs potently induce 
the differentiation of naïve T cells towards Th2 and IL-
10-producing Tr1 cells [22, 24]. In the same context as 
the results shown in Figure 6 and Supplementary Figure 
S6, we hypothesized that if IL-10 is a primary factor for 
inducing tolerogenic DCs and consequently polarizes 
CD4+ T cells towards Th2 and IL-10-producing Tr1 cells, 
the absence of IL-10 in DCs may prime the differentiation 
of CD4+ T cells towards Th1 and Th17 cells. Thus, we 
evaluated the capacity of IL-10-/- DCs to induce T cell 
proliferation, differentiation, and polarization using 
the same experimental conditions described in Figure 
6 (results shown in Figure 7). IL-10-/—derived DCs co-
treated with cisplatin and LPS induced the proliferation 
of both CD4+ and CD8+ T cells (Figure 7A) and polarized 
naïve CD4+ T cells towards Th1 and Th17 cells instead 
of Th2 and Tr1 cells (Figure 7B) compared with DCs 
derived from wild-type (WT) mice. Finally, we confirmed 
that IL-10-producing Tr1-type T cells were not induced 
by IL-10-/—derived DCs in the presence of cisplatin 
(Figure 7C). Collectively, these results indicate that 
cisplatin functionally and phenotypically induces DCs 
towards an IL-10-producing tolerogenic phenotype upon 
TLR stimulation. These tolerogenic DCs consequently 
contribute to the development of Th2 and IL-10-producing 
Tr1 cells, suggesting that IL-10 is a primary factor 
responsible for these cascades. 
In vivo tolerogenic activity of cisplatin-treated 
DCs
Based on the above in vitro results, we next 
examined whether cisplatin and LPS co-treated DCs 
could suppress Th1-cell proliferation and induce the 
differentiation of Th2 and Tr1 cells in vivo (Figure 8 
and Figure 9). Briefly, Ly5.1+ OT-I and OT-II T cells 
were transferred to Ly5.2+ recipient mice. The mice 
were intravenously injected with OVA protein-pulsed, 
LPS/cisplatin-primed DCs or OVA protein-pulsed, 
LPS-activated DCs one day after the T cell transfer. At 
5 and 7 days after the DC injections, we evaluated the 
frequencies and types of Ly5.1+ T cells induced by the 
LPS/cisplatin-primed DCs (Figure 8 and Figure 9) using 
flow cytometry. As shown in Figure 8, significantly 
reduced frequencies of Ly5.1+CD44+CD4+ cells and 
Ly5.1+CD44+CD8+ cells were found in the peripheral 
blood mononuclear cell (PBMC) (Figure 8A and 8B) and 
splenocyte (Figure 8C) populations isolated from the LPS/
cisplatin-primed DC group compared to the LPS-activated 
DC group. Importantly, the spleen cells isolated from the 
LPS/cisplatin-primed DCs group showed significantly 
reduced frequencies of Th1-type cells (IFN-γ-producing 
Ly5.1+CD4+ T cells) and IFN-γ-producing Ly5.1+CD8+ 
T cells compared with the LPS-primed DCs group in 
response to stimulation with OVA peptides (Figure 9A). 
Additionally, the LPS/cisplatin-primed DCs group showed 
significant induction of Th2-type cells (IL-4-producing 
Ly5.1+CD4+ T cells) and Tr1 cells (IL-10-producing 
Ly5.1+CD25-Foxp3-CD4+ T cells) (Figure 9A and 9B). 
Culture supernatants containing secreted cytokines were 
collected from the splenocytes following stimulation with 
OVA peptides and analyzed by ELISA. The results showed 
that the LPS/cisplatin-primed DCs group robustly secreted 
both Th2-related cytokines and Tr1-related cytokines such 
as IL-4 and IL-10, whereas they secreted significantly low 
levels of Th1-related (IFN-γ) and Th17-related (IL-17A) 
cytokines (Figure 9C). These results indicate that cisplatin-
treated DCs have in vivo tolerogenic activity by inducing 
the differentiation of Th2 and IL-10-producing Tr1 cells 
and decreasing the proliferation of CD4+ and CD8+ T cells. 
DISCUSSION
Although cisplatin is a common treatment for a 
broad spectrum of cancers, few studies have evaluated the 
effect of cisplatin treatment on the immune system. In the 
present study, we described the molecular mechanisms 
that are required for the immunosuppressive effect of 
cisplatin, including the phenotypic alteration of DCs 
and their interactions with T cells, thereby improving 
our understanding of the immunological aspects of this 
cancer chemotherapy. Cisplatin induced IL-10-producing 
tolerogenic DCs upon TLR agonist treatment by activating 
the p38 MAPK signaling pathway, and these cisplatin-
induced tolerogenic DCs promoted the generation of two 
distinct T cell subsets in vivo as well as in vitro: Th2-type 
T-cells and IL-10-producing Tr1 cells.
Several cancer drugs are also used as 
immunosuppressants for the treatment of severe systemic 
autoimmune diseases. Interestingly, cisplatin has shown 
therapeutic potential for treating inflammation-mediated 
diseases under different pathophysiological conditions [25, 
26]. For example, cisplatin was shown to ameliorate the 
symptoms of excessive inflammation-mediated diseases, 
such as experimental autoimmune encephalomyelitis 
(EAE), in vivo [25]. EAE is a prototypic Th1-mediated 
autoimmune inflammatory disease, and Th17 cells are 
assumed to be crucial effector cells that drive central 
nervous system (CNS) inflammation and damage [25, 27]. 
In addition, low-dose cisplatin administration in a murine 
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cecal ligation and puncture-induced polymicrobial sepsis 
model was found to attenuate inflammation and lethality 
[26]. Thus, cisplatin might be considered a candidate 
drug for the control of inflammatory and autoimmune 
processes. However, it remains unclear how cisplatin 
ameliorates excessive inflammation. Our findings help 
explain the immunomodulatory activities of cisplatin 
observed in these disease models. 
The nature of DCs determines the quality of T cell 
responses and the establishment of either immunity or 
tolerance. In a previous study, Dijkgraaf et al. showed that 
cisplatin treatment increased the PGE2-secreting potency 
of tumor cells to promote monocyte differentiation into IL-
10-producing M2 macrophages. These authors proposed a 
chemotherapy-induced increase in tumor-promoting M2 
macrophages may provide an indirect mechanism for 
chemoresistance and that concomitant therapy with COX 
inhibitors might enhance the anti-tumor effect of cisplatin 
[28]. Similarly, our data showed that cisplatin directly 
skewed the phenotype and function of DCs towards IL-10-
producing-tolerogenic DCs upon TLR ligand stimulation 
(Figure 2 and Supplementary Figure S3). However, the 
COX-2-PGE2 pathway did not induce tolerogenic DCs and 
IL-10 production in our study (Supplementary Figure S4). 
In addition, MyD88 or TRIF deficiency abrogated IL-10 
production in cisplatin and LPS co-treated DCs, indicating 
that TLR signaling is a prerequisite for the generation of 
IL-10-producing tolerogenic DCs (Supplementary Figure 
S5). Although it remains debatable whether the clinical 
success of cisplatin relies primarily on its ability to trigger 
apoptosis, cisplatin induces cell death mainly via apoptosis 
and eventually secondary necrosis, and endogenous TLR 
ligands are released during cell death. Along with the 
recognition of microbial TLR ligands called pathogen-
associated molecular patterns (PAMPs), an increasing 
number of endogenous TLR stimulators have been 
reported. These endogenous molecules activate TLR 
signaling and are involved in many pathological processes. 
For example, HMGB1 and heat shock proteins are either 
passively released from injured/inflamed tissues and 
dying cells or actively secreted by activated cells under 
pathological conditions. Furthermore, even apoptotic 
cells may release these endogenous TLR ligands [29]. In 
addition, a single endogenous molecule, such as HMGB1, 
has the potential to interact with several TLRs. Thus, 
these endogenous TLR ligands may participate in tumor 
progression. In addition, evidence indicates that dying 
tumor cells release endogenous TLR ligands [30-32]. In 
fact, HMGB1 released following chemotherapy-induced 
cell death activates DCs via the TLR4-MyD88 axis, which 
leads to the induction of anti-tumor T-cell immunity [30].
IL-10-producing tolerogenic DCs are potent 
inducers of naïve T cell differentiation towards Th2 
and IL-10-producing Tr1 cells [33]. During sterile 
inflammation caused by the exposure of normal cells to 
anti-cancer drugs, an enormous number of cells undergo 
apoptosis and/or necrosis in different organs and tissues. 
These dying cells release endogenous ligands, such as 
intracellular proteins and nucleic acids, which can bind 
to pattern recognition receptors, particularly those on 
tissue-resident innate immune cells such as DCs [34]. 
In response to activation signals, these cells can inhibit 
tissue damage by producing anti-inflammatory factors 
such as IL-10 [35]. However, because the large amounts 
of IL-10 that are present in the tumor microenvironment 
play a major role in suppressing the anti-tumor immune 
response, strategies to break tolerance by neutralizing 
the function of IL-10 are important for tumor treatment. 
In a recent study, renal DCs attenuated cisplatin-induced 
kidney inflammation by producing a high level of IL-10 
in response to cisplatin treatment [36]. In addition, in vivo 
cisplatin treatment directly caused a 10-fold increase of 
IL-10 production in renal DCs, but not in whole kidneys, 
indicating that DCs are the major source of IL-10 after 
cisplatin treatment [37]. However, little is known about 
the signaling pathways through which cisplatin triggers 
the generation of tolerogenic DCs after encountering 
inflammatory environments and their roles in preserving 
the tolerogenic properties of DCs. Our current study is 
the first to perform a detailed analysis of the molecular 
mechanisms responsible for the induction of tolerogenic 
DCs by cisplatin in the inflammatory environment. 
We found that a large amount of IL-10 was produced 
after cisplatin treatment and that this production was 
stimulated through the MAPK and NF-κB signaling 
pathways (Figure 3). Without an IL-10 signal, cisplatin-
treated DCs did not differentiate into tolerogenic DCs, 
indicating that induction of tolerogenic DCs by cisplatin 
requires IL-10 production (Figure 4 and Figure 5). There 
are several studies showing that p38 MAPK activation 
in immunosuppressive CD25- regulatory T cells [38] and 
tolerogenic DCs [39, 40] is a central pathway to induce 
IL-10 production. Our finding that cisplatin activates p38 
MAPK may explain why cisplatin treatment leads to the 
generation of IL-10-producing tolerogenic DCs. Moreover, 
the inhibition of p38 MAPK signaling in DCs has been 
suggested as a way to break immunological tolerance 
and redirect T cell responses to enhance anti-tumor 
immunity. The importance of IL-10 production by DCs in 
the induction of tolerance has been demonstrated, as DCs 
genetically modified to express IL-10 exhibit suppressive 
effects in models of alloreactivity and autoimmunity [41, 
42]. Jarnicki et al. further demonstrated that the inhibition 
of p38 MAPK-dependent IL-10 secretion by DCs led to 
stronger Th1 responses and reduced Tr1 induction [39], 
indicating that the immune tolerance that is induced by 
cisplatin can be overcome by inhibiting p38 signaling 
in DCs. Thus, p38 is an important therapeutic target and 
provides a mechanism to enhance the efficacy of TLR 
agonists as vaccine adjuvants together with anti-cancer 
drugs. 
One provocative finding of our study was 
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the induction of IL-10-producing CD3+CD4+LAG-
3+CD49b+CD25-Foxp3- Tr1 cells by cisplatin/LPS-primed 
DCs both in vitro and in vivo (Figure 6, Figure 8, Figure 
9 and Supplementary Figure S6). Tr1 cells are induced 
in the periphery and play a pivotal role in promoting and 
maintaining tolerance. IL-10-secreting Tr1 cells were 
first defined by their specific cytokine production profile, 
which includes the secretion of high levels of IL-10 and 
transforming growth factor-b (TGF-b), and by their ability 
to suppress antigen-specific effector T cell responses via 
a cytokine-dependent mechanism [43]. In other words, 
the induction of IL-10-secreting T-cell populations with 
regulatory activity is IL-10 dependent. In contrast to the 
naturally occurring Tregs that emerge directly from the 
thymus, Tr1 cells are induced by antigen stimulation via 
an IL-10-dependent process in vitro and in vivo. Thus, 
specialized IL-10-producing DCs may play a key role 
in this process. However, we cannot completely exclude 
the secondary effect of IL-10 produced from T cells in 
accelerating the differentiation of Tr1 cells, indicating that 
further study of the induction of Tr1 differentiation via 
interactions between IL-10-producing DCs and IL-10-
producing T cells is required. 
Many studies have suggested that chemotherapy 
resistance is associated with a strong immune-suppressive 
tumor microenvironment [44], and our data suggest 
a possible underlying mechanism for systemic tumor 
progression in cases of relapse after chemotherapy. 
Although current treatment protocols, including surgery 
and chemotherapy, can achieve local control of a tumor, 
patients who relapse after long-term cisplatin treatment 
may develop systemic disease due to the cisplatin-induced 
generation of tolerogenic DCs, which limit the Th1 
immune response.
In summary, we demonstrated that cisplatin 
reprograms TLR agonist-induced activation of DCs 
via p38 MAPK-induced IL-10 production to generate 
tolerogenic DCs, which in turn promote the differentiation 
of naïve CD4+ T cells into IL-10-producing Tr1 cells. A 
better understanding of the different effects of cisplatin 
on immune cells compared to cancer cells may lead to 
the design of more successful anti-tumor drugs and may 
also provide new therapeutic strategies based on cisplatin-
induced immunological modulation.
MATERIALS AND METHODS
Experimental animals
Specific pathogen-free, female, 6- to 8-week-old 
C57BL/6 (H-2Kb and I-Ab), BALB/c (H-2Kd and I-Ad), 
C57BL/6 IL-10-/-, C57BL/6 MyD88-/-, C57BL/6 TRIF-/-
, C57BL/6 OT-I and OT-II OVA specific T cell receptor 
(TCR) transgenic mice were purchased from The Jackson 
Laboratory (Bar Harbor, ME, USA). 
Antibodies and reagents
Recombinant mouse granulocyte-macrophage 
colony stimulating factor (GM-CSF) was purchased 
from R&D Systems (Minneapolis, MN, USA). 3-(4, 
5-dimethylthiazol-2-yl)-2, 5-diphenyl-tetrazolium bromide 
(MTT) was purchased from Sigma-Aldrich Chemical 
Co. (St Louis, MO, USA). Pam3CSK4, Poly I:C, 
lipopolysaccharide (LPS, from Escherichia coli O111:B4), 
Imiquimod (R837) and ODN1826 were purchased from 
Invivogen (San Diego, CA, USA). The OT-I peptide 
(OVA257-264, SIINFEKL) and OT-II peptide (OVA323-
339, ISQAVHAAHAEINEAGR) were synthesized by 
Abfrontier (Seoul, Korea). Anti-phosphorylated ERK1/2, 
JNK, and p38 mouse monoclonal antibodies (mAbs) and 
anti-ERK1/2, JNK, p38 mAbs were obtained from Santa 
Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). A 
horseradish peroxidase (HRP)-conjugated anti-mouse Ab 
and a HRP-conjugated anti-rabbit Ab were obtained from 
Calbiochem (San Diego, CA, USA). PE-conjugated mAbs 
to CD80, MHC-I, IFN-γ, IL-4, GATA-3 and Foxp3; PE-
Cy7-conjugated mAbs to CD11c, CD25 and T-bet; PerCP-
Cy5.5-conjugated mAbs to CD223 (LAG-3), CD4 and 
CD8; APC-conjugated mAbs to CD86, MHC-II, CD49b, 
IL-10, IL-12p70, TNF-α and RoRγt; APC-Cy7-conjugated 
CD127 mAb; BV510-conjugated IL-10 mAb; APC-Cy7-
conjugated IL-17A mAb; and a FITC-conjugated mAb to 
CD4 were purchased from eBioscience (San Diego, CA, 
USA). TNF-α, IL-2, IL-4, Th17A and IFN-γ ELISA kits 
were obtained from eBioscience. Anti-Armenian hamster 
IgG, anti-rat IgG2a K, anti-rat IgG2b, anti-mouse IgG1 
K and anti-mouse IgG2a isotype controls were purchased 
from eBioscience. Neutralizing anti-IL-10 mAb (JESS-
2A5) and isotype control rat IgG1 (HRPN) were purchased 
from Bio X Cell (West Lebanon, NH, USA). 
Differentiation of BMDCs
Whole bone marrow cells isolated from C57BL/6 
mice were incubated at 37°C in a 5% CO2 atmosphere 
using RPMI 1640 medium supplemented with 100 U/
mL penicillin/streptomycin (Lonza, Basel, Switzerland), 
10% fetal bovine serum (Lonza), 50 μM mercaptoethanol 
(Lonza), 0.1 mM nonessential amino acids (Lonza), 1 mM 
sodium pyruvate (Sigma Chemical Co., St. Louis, MO, 
USA) and GM-CSF (20 ng/mL). On day 8, over 80% 
of the non-adherent cells expressed CD11c. To obtain 
highly purified populations ( > 95% cell purity), in some 
experiments, the DCs were labeled with a bead-conjugated 
anti-CD11c mAb (Miltenyi Biotec, Bergisch Gladbach, 
Germany) followed by positive selection on paramagnetic 
columns (LS columns; Miltenyi Biotec) according to the 
manufacturer’s instructions.
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Annexin V and propidium iodide (PI) assay using 
flow cytometry
After 8 days of culture, BMDCs were treated with 
LPS and/or cisplatin. After 18 h of treatment, harvested 
DCs were washed with PBS and stained using the Annexin 
V-PI Apoptosis Detection kit (BD Biosciences) protocol. 
Cell survival assay
Cell viability was measured by MTT assay. MTT 
was dissolved in PBS at a final concentration of 0.5 mg/
ml. A 100-μl aliquot of the MTT solution was added to 
each well of a 96-well plate, and the plate was incubated 
at 37°C for 4 h. The resultant formazan crystals were 
dissolved in DMSO, and the OD570 nm values of each 
well were measured using a microplate reader. 
Analysis of DC surface molecule expression using 
flow cytometry
On day 8, BMDCs were harvested, washed once, 
resuspended at 1×106 cells/ml, and treated with the 
following stimuli for 18 h: medium alone (CON; control), 
LPS, cisplatin, or LPS and cisplatin. The cells were first 
blocked with 10% (v/v) normal goat serum for 15 min 
at 4°C and then stained with anti-MHC-I, anti-MHC-II, 
anti-CD80, anti-CD86, and anti-CD11c mAbs for 30 min 
at 4°C. Finally, the stained cells were analyzed using an 
LSRII flow cytometer (Becton Dickinson, San Jose, CA, 
USA) and FlowJo software (Tree Star, Inc., Ashland, OR). 
ELISA
To assess cytokine production, supernatants were 
collected 18 h after treatment of DCs and stored at −70°C. 
The amounts of TNF-α, IL-12p70, IL-10, IFN-γ, IL-2, 
IL-4 and IL-17A were measured by sandwich ELISA 
kits using commercially available pairs of antibodies and 
standards according to the manufacturer’s protocol. 
Intracellular cytokine staining
Cells were first blocked with 10% (v/v) normal goat 
serum for 15 min at 4°C and then stained with CD11c, 
CD4 and CD8 mAbs for 30 min at 4°C. Cells stained with 
the appropriate isotype-matched IgG were used as negative 
controls. The cells were fixed and permeabilized with a 
Cytofix/Cytoperm kit (BD Biosciences or eBioscience) 
according to the manufacturer’s instructions. Next, anti-
IL-12p70, anti-IL-10, anti-TNF-α, anti-IFN-γ, anti-IL-4, 
anti-IL-17A, anti-T-bet, anti-GATA-3 and anti-RoRγt 
mAbs were stained with fluorescein-conjugated secondary 
Abs in a permeation buffer. 
Antigen uptake assay
BMDCs were equilibrated at 37°C or 4°C for 45 
min and then pulsed with fluorescein-conjugated dextran 
(40,000 Da) from Sigma-Aldrich (St. Louis, MO) at a 
concentration of 1 mg/ml. After several washes with 
cold phosphate-buffered solution, the cells were stained 
with a PE-Cy7-conjugated anti-CD11c mAb and then 
measured with a FACS LSRII to reveal antigen uptake. 
Nonspecific binding of dextran to DCs was determined by 
incubating DCs with FITC-conjugated dextran at 4°C, and 
the resulting background value was subtracted from the 
specific binding values. 
Immunoblotting analyses
After stimulation with LPS, cisplatin, or LPS 
and cisplatin, DCs were lysed in 100 μl lysis buffer 
containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 
1% Triton-X100, 1 mM EDTA, 50 mM NaF, 30 mM 
Na4PO7, 1 mM phenylmethanesulfonyl fluoride, 2 μg/
ml aprotinin, and 1 mM pervanadate. Whole-cell lysate 
samples were resolved on SDS-polyacrylamide gels 
and then transferred onto nitrocellulose membranes for 
1 h at 60 V. The membranes were blocked in 5% skim 
milk and incubated with primary Abs for 2 h, followed 
by incubation with HRP-conjugated secondary Abs for 
1 h at room temperature. Target protein epitopes were 
labeled with primary Abs against total MAPKs and IκB-α 
(1:1,000 diluted in blocking solution) and polyclonal Abs 
against p-ERK 1/2, p-JNK 1/2, p-p38, p-IκB-α and p65 
(1:5,000, 1:2,000, 1:5,000, 1:2,000 and 1:3,000 dilutions, 
respectively), and the results were visualized using an ECL 
Advance Western Blotting Detection kit (GE Healthcare, 
Little Chalfont, U.K.).
Nuclear extract preparation
BMDCs were treated with 150 μl lysis buffer [10 
mM HEPES (pH 7.9), 10 mM KCl, 0.1 mM EDTA, 
0.5% Nonidet P-40, 1 mM KCL, 1 mM dithiothreitol, 
0.5 mM PMSF] on ice for 15 min. After centrifugation 
at 3,000 rpm for 3 min, the pellet was resuspended in 
100 μl extraction buffer [10 mM HEPES (pH 7.9), 400 
mM NaCl, 1 mM EDTA, 1 mM DTT, 1 mM PMSF] and 
incubated on ice for 30 min, followed by centrifugation at 
12,000 rpm for 5 min. The supernatant containing nuclear 
extracts was collected.
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Treatment of DCs with pharmacological 
inhibitors
All pharmacological inhibitors were obtained 
from Calbiochem; reconstituted in sterile, cell-culture 
grade DMSO; and used at the following concentrations: 
SP600125 (1, 5 and 10 μM), SB203580 (1, 5 and 
10 μM) and Bay-117082 (5, 10 and 20 μM). A 0.1% 
DMSO solution was used as the vehicle control. For 
the experiments with inhibitors, cells were treated with 
pharmacological inhibitors for 1 h prior to treatment with 
a combination of LPS and cisplatin for 18 h.
Analysis of T cell differentiation and proliferation 
both in vitro and in vivo
T cell proliferation and differentiation were assayed 
in vitro and in vivo using a modified previously described 
protocol [45, 46]. Responder T cells, which participate 
in naive T cell reactions, were isolated using a MACS 
column from total mononuclear cells prepared from 
OT-I, OT-II and naive BALB/c mice. For the in vitro 
experiment, OVA-specific CD8+ and CD4+ T cells, both 
responders, were obtained from the splenocytes of OT-I 
and OT-II mice, respectively. These T cells were stained 
with 1 μM carboxyfluorescein diacetate succinimidyl 
ester (CFSE; Invitrogen). DCs (2×105 cells/well) treated 
with OVA peptide in the presence of LPS (100 ng/ml), 
cisplatin or a combination of LPS and cisplatin for 18 h 
were co-cultured with CFSE-stained CD8+ and CD4+ T 
cells (2×106) at a DC:T-cell ratio of 1:10. Naive BALB/c 
(allogeneic mixed lymphocyte reaction (MLR)) T cells 
(2×106) were co-cultured with DCs (2×105 cells/well) 
treated with LPS, cisplatin or LPS and cisplatin. On day 
3 or day 4 of co-culture, T cells were stained using an 
intracellular staining method. Culture supernatants were 
harvested, and IFN-γ, IL-2, IL-4 and IL-17A levels were 
measured by ELISA.
For the in vivo experiment, Ly5.1+ OT-I and OT-
II T cells (5 × 105 cells per population) were transferred 
intravenously into the lateral tail veins of Ly5.2+ recipient 
mice. The next day, BMDCs from Ly5.2+ recipient mice 
were pulsed with ovalbumin protein (10 μg/ml) for 2 h, 
and then the cells were washed with wash buffer (RPMI 
1640 plus 2% FBS). After washing twice with wash buffer, 
the DCs were stimulated by LPS with or without cisplatin 
for 18 h. These DCs (5 × 106 cells) were transferred 
intravenously into the lateral tail veins of Ly5.2+ recipient 
mice. At day 5 and day 7 after the DC transfer, PBMCs 
were isolated from blood samples collected from each 
mouse, as previously described [47]. To analyze the 
populations of Ly5.1+ OT-I and OT-II T cells, single-cell 
suspensions of PBMCs and splenocytes from each mouse 
were stained with anti-CD4, anti-CD8α, anti-CD44, and 
anti-Ly5.1 mAbs. Dead cells were excluded using a Live/
Dead Fixable Dead Cell Stain kit (Invitrogen). Data were 
collected on a FACS Canto II (BD) and a FACSverse 
(BD) and analyzed using FlowJo software (TreeStar). 
Additionally, single-cell suspensions prepared from the 
spleens of each group were stimulated with OVA257-264 
(0.2 μg/ml) and OVA323-339 (5 μg/ml) for 12 h at 37°C in 
the presence of GolgiPlug 7 days after DC transfer. At 12 
h after stimulation, the types and populations of T cells 
(Ly5.1+ T cells) present were analyzed by intercellular 
staining and flow cytometry. Supernatants were harvested, 
and IFN-γ, IL-4, IL-17A and IL-10 levels were measured 
by ELISA.
Statistical analysis
Significant differences between samples were 
determined with Tukey’s multiple comparison test and 
unpaired t-tests using statistical software (GraphPad Prism 
Software, version 5; GraphPad Software, San Diego, 
CA). The data in the graphs are expressed as the means. 
*p < 0.05, **p < 0.01 and ***p < 0.001 were considered 
statistically significant.
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